AUS
NZ
UK
CA
USA
IND
Highlights:
- Record Revenue Growth: Orthocell Ltd (ASX:OCC) reported A$2.21 million in revenue for Q4 FY2024, marking its third consecutive quarter of record-breaking results, with a 9% increase from the previous quarter.
- Global Market Expansion: Progress in international regulatory approvals is unlocking new markets, including the anticipated US FDA approval of Remplir™, targeting a US$1.6 billion nerve repair market by early 2025.
- Strategic Partnerships: Distribution partnerships with BioHorizons and Device Technologies continue driving market penetration across key regions for Striate+™ and Remplir™.
Orthocell Ltd (ASX:OCC) Continues Momentum with Record-Breaking Revenue Growth
Orthocell Ltd (ASX:OCC), a leader in regenerative medical devices, has sustained its impressive growth trajectory, achieving A$2.21 million in revenue for the December 2024 quarter. This marks the third consecutive quarter of record-breaking revenue, reflecting strong market demand and effective commercial strategies. The December 2024 quarter’s revenue represents a 9% increase from the prior record of A$2.03 million set in September and a 46% surge compared to the December 2023 quarter. These figures underscore Orthocell’s ability to deliver consistent growth even during traditionally slower periods.
Sustained Product Success
Orthocell’s revenue growth highlights the growing traction of its two flagship products: Striate+™, designed for dental bone regeneration and distributed globally by BioHorizons Implant Systems Inc., and Remplir™, a solution for peripheral nerve repair, distributed by Device Technologies in Australia, New Zealand, and Singapore. The clinical performance of these innovative devices has driven adoption among new and existing surgeons, showcasing their ability to deliver predictable and reliable outcomes.
Expansion into New Markets
Orthocell is advancing its global commercialisation strategy, targeting a total market opportunity of approximately US$4.5 billion across nine key regions, including the USA, Europe, UK, and Asia-Pacific. A significant milestone in this expansion is the expected US FDA approval for Remplir™, projected for March or April 2025. This regulatory approval would open access to the US$1.6 billion nerve repair market in the United States, setting the stage for exponential growth. The company is actively pursuing additional regulatory approvals in other jurisdictions, further broadening its market reach.
Distribution Partnerships Driving Penetration
Orthocell has established strategic partnerships to ensure widespread distribution: BioHorizons Implant Systems Inc. distributes Striate+ globally across regions like the USA, Europe, and Canada. Device Technologies supports Remplir’s distribution in Australia, New Zealand, and Singapore. These partnerships are crucial for driving uptake and enabling rapid market penetration in regulated regions.
Financial Strength Supports Aggressive Growth
Orthocell is well-positioned to sustain its growth with a solid financial foundation. The company holds approximately $31 million in cash reserves, complemented by an expected R&D rebate of around $3 million in the current quarter. This robust cash position allows the company to execute its ambitious expansion and engagement strategies.
Strategic Engagement
Orthocell’s strategy includes targeted clinician engagement and regulatory alignment to accelerate market access in new territories. The company’s comprehensive approach aims to maximize the global potential of its product portfolio. As additional regulatory approvals are secured, Orthocell is poised to further capitalize on its growth trajectory, reinforcing its position as a key player in the US$4.5 billion global regenerative medical device market.
